Torrey Pines Law Group Torrey Pines Law GroupFree Consultation
≡
  • About Us
    • About Our Firm
    • The Advantages of Hiring Our Firm
    • Recent Successes
    • Client Testimonials
    • Careers
    • Diversity
    • Locations
    • San Diego
      • San Diego Patent Atorneys
      • San Diego FDA Regulatory Counsel
      • San Diego Technology Transactions
    • Irvine
      • Irvine Patent Atorneys
      • Irvine FDA Regulatory Counsel
      • Irvine Technology Transactions
    • Los Angeles
      • Los Angeles Patent Atorneys
      • Los Angeles FDA Regulatory Counsel
      • Los Angeles Technology Transactions
    • Contact
  • Professionals
    • Meet Our Team
    • Kevin Buckley, JD
    • Edgar Asebey, JD
    • Frank Chen, PhD
    • Nach Davé, MS, RPh
    • Elie Gendloff, PhD, JD
    • Dmitry Kryndushkin, PhD
    • Mark Malek, JD
    • Eleanor Musick, JD
    • Steven Stupp, PhD
    • Neil Thompson, MS
    • Kyle Welch, JD
    • Jian Yang, PhD
    •  
    • Administration
    • Suzanne Baycan
    • Carina Collins
    • Erika Hamer
    • Cyndi Willis
    •  
    • Foreign Associates
  • Intellectual Property
    • Comprehensive IP Protection
    • Patent Preparation & Prosecution
    • ● Artificial Intelligence Patent Lawyers
    • ● Biotechnology Patent Lawyers
    • ● Chemistry & Chemical Engineering Patent Lawyers
    • ● Convergence Technology Patent Lawyers
    • ● Electronics & Software Patent Lawyers
    • ● In Vitro Diagnostics Patent Lawyers
    • ● Medical Device Patent Lawyers
    • ● Pharmaceutical Patent Lawyers
    • ● Pharmaceutical Lifecycle Management
    • National Phase Entry (PCT)
    • IP Litigation
    • IP Opinions & Counseling
    • IP Resources
      • Patent Rights Overview
      • International Patent Law
      • U.S. Patent Law
        • Patent Eligibility
        • Novelty
        • Obviousness
        • Written Description
        • Enablement
      • Anatomy of a U.S. Patent
        • Utility Patent
        • Design Patent
        • Plant Patent
      • Trademark Law
      • Copyright Law
      • Trade Secrets
      • Know How
      • Intangible Assets
  • FDA Regulatory
    • Global Strategic Counseling
    • Dossier Submissions
    • Quality Compliance (ISO)
    • CE Mark - MDR Services
    • Digital Health
    • Hatch-Waxman & Biosimilars
    • Labeling, Advertising & Promotion
    • Reimbursement & Health Economics
  • Tech Transactions
    • International Technology Transactions
    • Intellectual Property Agreements
    • Intellectual Property Due Diligence
    • Regulatory Agreements
    • Regulatory Due Diligence
    • Business Agreements
    • Transactional Due Diligence
    • Corporate Strategy
  • Experience
    • Our International Experience
    • Multinational Companies
    • Public Companies
    • Private Companies
    • Research & Academic Institutions
    • Hospitals & Physicians
    • Startups & Entrepreneurs
background
Hide
 
Show
  • background
  • torrey-pines-broken-hill
  • torrey-pines-sunset

Patent Enablement

Patent Enablement

How to Make and Use an Invention Without "Undue" Experimentation

Under 35 U.S.C. §112(a), courts use the “Wands factors” to help determine whether the disclosure meets the enablement standard. These factors include:

  • The quantity of experimentation necessary,
  • The amount of direction or guidance presented,
  • The presence or absence of working examples,
  • The nature of the invention,
  • The state of the prior art,
  • The relative skill of those in the art,
  • The predictability or unpredictability of the art, and
  • The breadth of the claims.

In re Wands, 858 F.2d 731 (Fed. Cir. 1988).

Whether a patent application is enabled is also dependent upon the subject matter of the invention. A line of cases related to "predictable" inventions suggests that a single example of making and using the claimed invention is sufficient for enabling a person to practice the scope of patent application without undue experimentation. In a second line of cases related to "unpredictable" inventions such as biotechnology, pharmaceutical, and to a lesser degree medical device inventions, courts have held that a range of examples is desired to meet the enablement requirement.

Thus, it is our practice at Torrey Pines Law Group to describe as many alternative embodiments of an unpredictable invention as possible. If a variety of homologous polynucleotide or polypeptide sequences are effective in the invention, we ask our clients to descbibe them in examples. Examples are likewise requested with respect to alternative vectors, cell lines, salts, indications, analogs, algorithms, and the like. This provides the best opportunity to fully enable a patent application and issued patent.

≡
  • Comprehensive IP Protection
  • Patent Preparation & Prosecution
  • ● Artificial Intelligence Patent Lawyers
  • ● Biotechnology Patent Lawyers
  • ● Chemistry & Chemical Engineering Patent Lawyers
  • ● Convergence Technology Patent Lawyers
  • ● Electronics & Software Patent Lawyers
  • ● In Vitro Diagnostics Patent Lawyers
  • ● Medical Device Patent Lawyers
  • ● Pharmaceutical Patent Lawyers
  • ● Pharmaceutical Lifecycle Management
  • National Phase Entry (PCT)
  • IP Litigation
  • IP Opinions & Counseling
  • IP Resources
    • Patent Rights Overview
    • International Patent Law
    • U.S. Patent Law
      • Patent Eligibility
      • Novelty
      • Obviousness
      • Written Description
      • Enablement
    • Anatomy of a U.S. Patent
      • Utility Patent
      • Design Patent
      • Plant Patent
    • Trademark Law
    • Copyright Law
    • Trade Secrets
    • Know How
    • Intangible Assets

Torrey Pines Law Group, PC BBB Business Review Torrey Pines Law Group LinkedIn COPYRIGHT © , TORREY PINES LAW GROUP, PC. ALL RIGHTS RESERVED. | LEGAL NOTICES | SITE MAP | PAYMENTS | STANDARD FIRM CHARGES

Torrey Pines Law Group, PC serves technology innovators with protecting intellectual property, obtaining regulatory approvals and clearances, and making deals and closing technology transactions throughout the U.S., including in major technology hubs such as San Diego, San Francisco, Palo Alto, San Jose, Silicon Valley, Boston, Cambridge, Chicago, Minneapolis, Houston, Dallas, Atlanta, Denver, Seattle, Portland, Boulder, Orlando, the Research Triangle (Raleigh, Durham, and Chapel Hill), the Mid-Atlantic (New Jersey, New York, Philadelphia, Maryland, Virginia, and Washington, DC), Pittsburgh, Cleveland, Ann Arbor, and throughout Southern California in Los Angeles, Orange County, Irvine, Torrey Pines, Sorrento Valley, and La Jolla.

We have experience with international intellectual property, regulatory and transactional matters pending in Beijing, Shanghai, Shenzhen, and Guangzhou China; Tokyo, Japan; Berlin, Munich and Frankfurt Germany; Tel Aviv Israel; Mumbai, Bengaluru, and New Delhi India; London and Edinburgh United Kingdom; Vancouver, Toronto, Calgary and Montreal Canada; Dublin, Ireland; Cape Town, South Africa; Mexico City and Tijuana Mexico; Brussels, Belgium; Copenhagen, Denmark; Paris, France; Madrid and Barcelona Spain; Moscow, Russia; Santiago, Chile; Montevideo, Uruguay; Buenos Aires, Argentina; Sao Paulo and Rio de Janeiro Brazil; Seoul, South Korea; Taipei, Taiwan; Hong Kong; Hanoi, Vietnam; Bangkok, Thailand; Kuala Lumpur, Malaysia; Milan, Italy; Singapore; Sydney, Melbourne, Perth and Adelaide Australia; Auckland, New Zealand; Oslo, Norway; Stockholm, Sweden; Helsinki, Finland; Kiev, Ukraine; Budapest, Hungary; Vienna, Austria; Prague, Czechia; Geneva and Lausanne Switzerland; Bahrain; Doha, Qatar; Abu Dhabi and Dubai UAE; and Jeddah, Saudi Arabia.

San Diego Patent Enablement Law Firm - Orange County Patent Enablement Counsel - Los Angeles Patent Enablement Opinions - International Patent Enablement Law